The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
Open accessAbstract
Introduction: Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype. Methods: We defined two independent molecular signatures of the PI3K pathway: a proteomic (reverse-phase proteomic array) PI3K signature, based on protein measurement for PI3K signaling intermediates, and a PI3K transcriptional (mRNA) signature based on the set of genes either induced or repressed by PI3K inhibitors. By using these signatures, we scored each ER+ breast tumor represented in multiple independent expression-profiling datasets (four mRNA, n = 915; one protein, n = 429) for activation of the PI3K pathway. Effects of PI3K inhibitor BEZ-235 on ER expression and activity levels and cell growth were tested by quantitative real-time PCR and cell proliferation assays. Results: Within ER+ tumors, ER levels were negatively correlated with the PI3K activation scores, both at the proteomic and transcriptional levels, in all datasets examined. PI3K signature scores were also higher in ER+ tumors and cell lines of the more aggressive luminal B molecular subtype versus those of the less aggressive luminal A subtype. Notably, BEZ-235 treatment in four different ER+ cell lines increased expression of ER and ER target genes including PR, and treatment with IGF-I (which signals via PI3K) decreased expression of ER and target genes, thus further establishing an inverse functional relation between ER and PI3K. BEZ-235 had an additional effect on tamoxifen in inhibiting the growth of a number of ER+ cell lines. Conclusions: Our data suggest that luminal B tumors have hyperactive GFR/PI3K signaling associated with lower ER levels, which has been correlated with resistance to endocrine therapy. Targeting PI3K in these tumors might reverse loss of ER expression and signaling and restore hormonal sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationStatistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Self-citationJava Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Self-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Self-citationCreighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Self-citationAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationDesmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Self-citationMajumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 837
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
Self-citationTibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718
Self-citationArpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Self-citationOncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Self-citationMassarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Self-citationSteroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Self-citationPerren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Osborne, C. K., & Schiff, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.036 · Cited by 351
Self-citationThe phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
Dillon, R. L., White, D. E., & Muller, W. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210202 · Cited by 311
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303
EGFR associated expression profiles vary with breast tumor subtype
Hoadley, K. A., Weigman, V. J., Fan, C., Sawyer, L. R., He, X., Troester, M. A., Sartor, C. I., Rieger-House, T., Bernard, P. S., Carey, L. A., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-258 · Cited by 278
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M. (2005) · The Journal of Pathology · doi:10.1002/path.1829 · Cited by 268
Creighton, C. J., Casa, A., Lazard, Z., Huang, S., Tsimelzon, A., Hilsenbeck, S. G., Osborne, C. K., & Lee, A. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4429 · Cited by 260
Self-citationCreighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El-Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243
Self-citationKim, H.-J., Litzenburger, B. C., Cui, X., Delgado, D. A., Grabiner, B. C., Lin, X., Lewis, M. T., Gottardis, M. M., Wong, T. W., Attar, R. M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01315-06 · Cited by 241
Self-citationCui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Self-citationDeregulation of the Akt Pathway in Human Cancer
Tokunaga, E., Oki, E., Egashira, A., Sadanaga, N., Morita, M., Kakeji, Y., & Maehara, Y. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497140 · Cited by 220
Activation of PI3K/Akt signaling and hormone resistance in breast cancer
Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Morita, M., Kakeji, Y., Baba, H., & Maehara, Y. (2006) · Breast Cancer · doi:10.2325/jbcs.13.137 · Cited by 199
Dhasarathy, A., Kajita, M., & Wade, P. A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0293 · Cited by 174
Guo, S., & Sonenshein, G. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8681-8690.2004 · Cited by 168
Akt kinases in breast cancer and the results of adjuvant therapy
Stål, O., Pérez-Tenorio, G., Åkerberg, L., Olsson, B., Nordenskjöld, B., Skoog, L., & Rutqvist, L. E. (2003) · Breast Cancer Research · doi:10.1186/bcr569 · Cited by 167
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin, N., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0946 · Cited by 137
Progesterone Receptors in Mammary Gland Development and Tumorigenesis
Conneely, O. M., Jericevic, B. M., & Lydon, J. P. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1025952924864 · Cited by 133
Pharmacodynamic Markers of Perifosine Efficacy
Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H. S., Carey, M. S., Ravoori, M. K., Gonzalez-Angulo, A. M., Birch, R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0760 · Cited by 131
Self-citationAllelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
Garcia, J. M., Silva, J. M., Domínguez, G., Gonzalez, R. M., Navarro, A., Carretero, L., Provencio, M., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006273516976 · Cited by 122
Bayliss, J. M., Hilger, A., Vishnu, P., Diehl, K. M., & El‐Ashry, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0587 · Cited by 114
Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Chen, Y., Law, P. C., & Loh, H. H. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/156801105774574649 · Cited by 113
Dysregulated PTEN‐PKB and negative receptor status in human breast cancer
Shi, W., Zhang, X., Pintilie, M., Ma, N., Miller, N. A., Banerjee, D., Tsao, M., Mak, T. W., Fyles, A., & Liu, F. (2003) · International Journal of Cancer · doi:10.1002/ijc.10909 · Cited by 87
Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma
Gibbons, D. L., Lin, W., Creighton, C. J., Zheng, S., Berel, D., Yang, Y., Raso, M. G., Liu, D. D., Wistuba, I. I., Lozano, G., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005401 · Cited by 85
Self-citationA gene transcription signature of the Akt/mTOR pathway in clinical breast tumors
Creighton, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210245 · Cited by 73
Self-citationThe Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm
López‐Tarruella, S., & Schiff, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1399 · Cited by 61
Self-citationHER2が増幅されPI3K3CAが変異した乳癌細胞におけるPI3K/mTor二重阻害剤NVP‐BEZ235による特異的アポトーシス誘発
Saskia, M. B., Irmgard, H., Christian, S., et al. (2009) · Cited by 60
Generali, D., Fox, S. B., Brizzi, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1046 · Cited by 55
Activated Akt expression in breast cancer: Correlation with p53, Hdm2 and patient outcome
Vestey, S. B., Sen, C., Calder, C. J., Perks, C. M., Pignatelli, M. N., & Winters, Z. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.011 · Cited by 49
Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?
Bedard, P. L., Freedman, O. C., Howell, A., & Clemons, M. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9606-8 · Cited by 46
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationNeuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion
Venkatesh, H. S., Johung, T. B., Caretti, V., Noll, A., Tang, Y., Nagaraja, S., Gibson, E. M., Mount, C. W., Polepalli, J., Mitra, S. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.012 · Cited by 963
Metadata
- Authors
- Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., Osborne, C. K., Mills, G. B., Lee, A. V., & Schiff, R.
- Venue
- Breast Cancer Research
- Published
- 2010-06-22
- Volume
- 12
- Issue
- 3
- Pages
- R40-R40
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2115950635
- Cited by
- 258
- References
- 55
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.